Proteostasis Therapeutics Inc (NASDAQ:PTI) major shareholder Enterprise Associates 12 New bought 2,000,000 shares of Proteostasis Therapeutics stock in a transaction on Monday, December 18th. The shares were bought at an average cost of $5.00 per share, with a total value of $10,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Proteostasis Therapeutics Inc (PTI) traded down $0.20 during midday trading on Friday, hitting $5.04. The stock had a trading volume of 1,123,304 shares, compared to its average volume of 2,250,000. Proteostasis Therapeutics Inc has a 52 week low of $1.41 and a 52 week high of $16.67. The stock has a market capitalization of $166.89 and a price-to-earnings ratio of -2.28.
Proteostasis Therapeutics (NASDAQ:PTI) last issued its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.16. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%. The company had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.38 million. sell-side analysts predict that Proteostasis Therapeutics Inc will post -2.47 EPS for the current fiscal year.
A number of research firms have weighed in on PTI. ValuEngine lowered Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Proteostasis Therapeutics in a report on Tuesday, December 19th. Leerink Swann boosted their price objective on Proteostasis Therapeutics from $6.00 to $8.00 in a report on Tuesday, December 12th. Robert W. Baird boosted their price objective on Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research lowered Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $16.00.
A number of large investors have recently added to or reduced their stakes in PTI. LMR Partners LLP bought a new stake in Proteostasis Therapeutics in the 2nd quarter worth approximately $127,000. Jennison Associates LLC lifted its position in Proteostasis Therapeutics by 6.2% in the 2nd quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock worth $9,713,000 after buying an additional 120,575 shares during the last quarter. FMR LLC lifted its position in Proteostasis Therapeutics by 2.3% in the 2nd quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after buying an additional 66,111 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Proteostasis Therapeutics in the 2nd quarter worth approximately $296,000. Finally, Bain Capital Public Equity Management LLC bought a new stake in Proteostasis Therapeutics in the 2nd quarter worth approximately $1,233,000. Institutional investors own 51.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/13/insider-buying-proteostasis-therapeutics-inc-pti-major-shareholder-buys-10000000-00-in-stock.html.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.